Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLI) released its earnings results on Monday. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02), Zacks reports.

Brainstorm Cell Therapeutics Price Performance

NASDAQ:BCLI opened at $1.19 on Monday. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.25. The company has a fifty day moving average price of $1.71 and a 200 day moving average price of $2.00. The stock has a market cap of $6.79 million, a P/E ratio of -0.25 and a beta of 0.74.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 26th. They set a “hold” rating for the company.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.